Sagimet Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	2	2	-	-	-	-
Gross Profit	2	2	-	-	-	-
Selling, General & Admin	14.19	12.96	6.14	4.38	3.22	5.86
Research & Development	20.55	19.78	24.92	19.34	8.18	8.39
Operating Expenses	34.74	32.74	31.06	23.72	11.4	14.25
Operating Income	-32.74	-30.74	-31.06	-23.72	-11.4	-14.25
Interest Expense	-	-	-	-	-	-0.06
Interest & Investment Income	4.82	2.86	0.55	0.03	0.03	0.03
Other Non Operating Income (Expenses)	0.01	0	0	-0.75	-	-0.07
EBT Excluding Unusual Items	-27.92	-27.88	-30.5	-24.44	-11.37	-14.36
Other Unusual Items	-	-	-	-	-	0.1
Pretax Income	-27.92	-27.88	-30.5	-24.44	-11.37	-14.26
Net Income	-27.92	-27.88	-30.5	-24.44	-11.37	-14.26
Net Income to Common	-27.92	-27.88	-30.5	-24.44	-11.37	-14.26
Shares Outstanding (Basic)	18	10	0	0	0	-
Shares Outstanding (Diluted)	18	10	0	0	0	-
Shares Change (YoY)	9460.29%	5565.90%	50.61%	26.95%	-	-
EPS (Basic)	-1.58	-2.66	-165.20	-199.40	-117.75	-
EPS (Diluted)	-1.58	-2.66	-165.20	-199.40	-117.75	-
Free Cash Flow	-22.89	-23.77	-24.49	-21.71	-10.42	-10.55
Free Cash Flow Per Share	-1.30	-2.27	-132.65	-177.11	-107.87	-
Gross Margin	100.00%	100.00%	-	-	-	-
Operating Margin	-1637.15%	-1537.00%	-	-	-	-
Free Cash Flow Margin	-1144.50%	-1188.30%	-	-	-	-
EBITDA	-	-	-	-	-11.4	-14.25
D&A For EBITDA	-	-	-	-	0	0
EBIT	-32.74	-30.74	-31.06	-23.72	-11.4	-14.25
Revenue as Reported	2	2	-	-	-	-

Source: S&P Capital IQ. Standard template.